7p4e - Revision history

OCA at 13:01, 1 February 2024

2024-02-01T13:01:16Z

← Older revision		Revision as of 13:01, 1 February 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[7p4e]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7P4E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7P4E FirstGlance]. <br>		<table><tr><td colspan='2'>[[7p4e]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7P4E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7P4E FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5IV:~{N}-[[4-(cyclopropylsulfonylamino)-2-(trifluoromethyl)phenyl]methyl]-1-[(3-fluorophenyl)methyl]indole-5-carboxamide'>5IV</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.4Å</td></tr>
			<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5IV:~{N}-[[4-(cyclopropylsulfonylamino)-2-(trifluoromethyl)phenyl]methyl]-1-[(3-fluorophenyl)methyl]indole-5-carboxamide'>5IV</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7p4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7p4e OCA], [https://pdbe.org/7p4e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7p4e RCSB], [https://www.ebi.ac.uk/pdbsum/7p4e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7p4e ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7p4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7p4e OCA], [https://pdbe.org/7p4e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7p4e RCSB], [https://www.ebi.ac.uk/pdbsum/7p4e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7p4e ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
	[[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[https://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[https://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[https://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.		[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[https://omim.org/entry/601665 601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[https://omim.org/entry/604367 604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[https://omim.org/entry/137800 137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
	== Function ==		== Function ==
	[[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>		[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>

			==See Also==
			*[[Peroxisome proliferator-activated receptor 3D structures\|Peroxisome proliferator-activated receptor 3D structures]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 06:41, 8 September 2022

2022-09-08T06:41:04Z

← Older revision		Revision as of 06:41, 8 September 2022
Line 1:		Line 1:

	==Crystal structure of PPARgamma in complex with compound FL217==		==Crystal structure of PPARgamma in complex with compound FL217==
	<StructureSection load='7p4e' size='340' side='right'caption='[[7p4e]]' scene=''>		<StructureSection load='7p4e' size='340' side='right'caption='[[7p4e]], [[Resolution\|resolution]] 2.40Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7P4E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7P4E FirstGlance]. <br>		<table><tr><td colspan='2'>[[7p4e]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7P4E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7P4E FirstGlance]. <br>
	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7p4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7p4e OCA], [https://pdbe.org/7p4e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7p4e RCSB], [https://www.ebi.ac.uk/pdbsum/7p4e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7p4e ProSAT]</span></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5IV:~{N}-[[4-(cyclopropylsulfonylamino)-2-(trifluoromethyl)phenyl]methyl]-1-[(3-fluorophenyl)methyl]indole-5-carboxamide'>5IV</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
			<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7p4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7p4e OCA], [https://pdbe.org/7p4e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7p4e RCSB], [https://www.ebi.ac.uk/pdbsum/7p4e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7p4e ProSAT]</span></td></tr>
	</table>		</table>
			== Disease ==
			[[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[https://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[https://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[https://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
			== Function ==
			[[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>
			== References ==
			<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
			[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Chaikuad A]]		[[Category: Chaikuad A]]

OCA at 16:12, 6 July 2022

2022-07-06T16:12:24Z

← Older revision		Revision as of 16:12, 6 July 2022
Line 1:		Line 1:
	~~'''Unreleased structure'''~~

	~~The entry~~ 7p4e is ~~ON HOLD until Paper Publication~~		==Crystal structure of PPARgamma in complex with compound FL217==
			<StructureSection load='7p4e' size='340' side='right'caption='[[7p4e]]' scene=''>
	~~Authors~~: Ni, X., ~~Lillich~~, F., ~~Proschak, E~~., ~~Chaikuad, A~~.~~, Knapp, S~~.~~, Structural Genomics Consortium (SGC)~~		== Structural highlights ==
			<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7P4E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7P4E FirstGlance]. <br>
	~~Description: Crystal structure of PPARgamma in complex with compound FL217~~		</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7p4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7p4e OCA], [https://pdbe.org/7p4e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7p4e RCSB], [https://www.ebi.ac.uk/pdbsum/7p4e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7p4e ProSAT]</span></td></tr>
	[[Category: ~~Unreleased~~ Structures]]		</table>
	[[Category: Chaikuad, A]]		__TOC__
	[[Category: ~~Proschak, E~~]]		</StructureSection>
	[[Category: Lillich, F]]		[[Category: Large Structures]]
	[[Category: Ni, X]]		[[Category: Chaikuad A]]
	[[Category: ~~Knapp, S]]~~		[[Category: Knapp S]]
	~~[[Category: Structural Genomics Consortium (Sgc)~~]]		[[Category: Lillich F]]
			[[Category: Ni X]]
			[[Category: Proschak E]]

OCA at 06:25, 22 June 2022

2022-06-22T06:25:25Z

← Older revision		Revision as of 06:25, 22 June 2022
Line 7:		Line 7:
	Description: Crystal structure of PPARgamma in complex with compound FL217		Description: Crystal structure of PPARgamma in complex with compound FL217
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	~~[[Category: Ni, X]]~~
	[[Category: Chaikuad, A]]		[[Category: Chaikuad, A]]
	[[Category: Proschak, E]]		[[Category: Proschak, E]]
			[[Category: Lillich, F]]
			[[Category: Ni, X]]
	[[Category: Knapp, S]]		[[Category: Knapp, S]]
	~~[[Category: Lillich, F]]~~
	[[Category: Structural Genomics Consortium (Sgc)]]		[[Category: Structural Genomics Consortium (Sgc)]]

OCA at 05:02, 11 August 2021

2021-08-11T05:02:41Z

← Older revision		Revision as of 05:02, 11 August 2021
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 7p4e is ON HOLD		The entry 7p4e is ON HOLD until Paper Publication

	Authors: Ni, X., Lillich, F., Proschak, E., Chaikuad, A., Knapp, S., Structural Genomics Consortium (SGC)		Authors: Ni, X., Lillich, F., Proschak, E., Chaikuad, A., Knapp, S., Structural Genomics Consortium (SGC)

OCA: Protected "7p4e" [edit=sysop:move=sysop]

2021-07-21T07:55:12Z

Protected "7p4e" [edit=sysop:move=sysop]

← Older revision	Revision as of 07:55, 21 July 2021
(No difference)

OCA: New page: '''Unreleased structure''' The entry 7p4e is ON HOLD Authors: Ni, X., Lillich, F., Proschak, E., Chaikuad, A., Knapp, S., Structural Genomics Consortium (SGC) Description: Crystal stru...

2021-07-21T07:55:11Z

New page: '''Unreleased structure''' The entry 7p4e is ON HOLD Authors: Ni, X., Lillich, F., Proschak, E., Chaikuad, A., Knapp, S., Structural Genomics Consortium (SGC) Description: Crystal stru...

New page

'''Unreleased structure'''

The entry 7p4e is ON HOLD

Authors: Ni, X., Lillich, F., Proschak, E., Chaikuad, A., Knapp, S., Structural Genomics Consortium (SGC)

Description: Crystal structure of PPARgamma in complex with compound FL217
[[Category: Unreleased Structures]]
[[Category: Ni, X]]
[[Category: Chaikuad, A]]
[[Category: Proschak, E]]
[[Category: Knapp, S]]
[[Category: Lillich, F]]
[[Category: Structural Genomics Consortium (Sgc)]]